Normal Mid-Gestation Fetal Ultrasonography Cannot Reliably Exclude Severe Perinatal Hypophosphatasia.


Journal

Hormone research in paediatrics
ISSN: 1663-2826
Titre abrégé: Horm Res Paediatr
Pays: Switzerland
ID NLM: 101525157

Informations de publication

Date de publication:
2021
Historique:
received: 08 05 2021
accepted: 22 07 2021
pubmed: 27 8 2021
medline: 1 4 2022
entrez: 26 8 2021
Statut: ppublish

Résumé

Hypophosphatasia is a systemic bone disease characterized by inhibition of bone mineralization due to mutations in the ALPL gene that results in a deficiency of tissue nonspecific alkaline phosphatase. The perinatal form is the most severe. In the past, this form was lethal, although human recombinant enzyme replacement therapy has now been developed and licensed, which improves survival. Perinatal hypophosphatasia is usually suggested on antenatal ultrasonography with undermineralization of the long bones, skull, and thoracic cavity. In the UK, antenatal ultrasonography for fetal anomalies is conducted at mid-gestation (i.e., 18-21 weeks gestational age), and if normal, no further routine scans are performed. Usually, this would identify abnormalities in bone mineralization suggestive of perinatal hypophosphatasia. We describe 2 cases of perinatal hypophosphatasia where mid-gestation ultrasonography was normal. In the first case, where a previous pregnancy had been terminated for perinatal hypophosphatasia, third trimester ultrasonography revealed skeletal features of hypophosphatasia. In the second case, the diagnosis of perinatal hypophosphatasia was made only immediately after birth. We conclude that serial antenatal ultrasonography or antenatal genetic testing should be considered in all pregnancies with a positive family history of hypophosphatasia, as mid-gestation ultrasonography cannot reliably exclude perinatal hypophosphatasia. This is especially important given that effective enzyme replacement therapy is now available.

Identifiants

pubmed: 34438404
pii: 000519209
doi: 10.1159/000519209
doi:

Substances chimiques

ALPL protein, human EC 3.1.3.1
Alkaline Phosphatase EC 3.1.3.1

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

307-312

Informations de copyright

© 2021 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Amish Chinoy (A)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom.

Chibuike Iruloh (C)

Fetal Medicine Unit, St. Mary's Hospital, Manchester, United Kingdom.

Bronwyn Kerr (B)

Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.

M Zulf Mughal (MZ)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom.

Raja Padidela (R)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH